StreetInsider.com News Articles

Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th

Thu, 10 Sep 2026 16:05:00 -0400

GAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer; Dr. Michelle Williams, Chief Scientific Officer; and Matthew Ferguson, Chief Financial Officer, will present and host one-on-one meetings with investors at the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York City on September 15–16, 2026.

During the presentation, management will discuss how Elutia is working to address post-surgical infection in plastic and reconstructive surgeries—one of the

Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th

Thu, 10 Sep 2026 16:05:00 -0400

During the presentation, management will discuss how Elutia is working to address post-surgical infection in plastic and reconstructive surgeries—one of the

Form 8-K ELUTIA INC. For: Aug 17

Fri, 21 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260821/26962310.html

Form 8-K ELUTIA INC. For: Aug 17

Fri, 21 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260821/26962310.html

Cellution Biologics buys SimpliDerm from Elutia for up to $11M

Tue, 18 Aug 2026 11:19:53 -0400

Cellution Biologics Inc. has completed its acquisition of the SimpliDerm hydrated human acellular dermal matrix business from Elutia Inc. (Nasdaq: ELUT), according to a press release from the company.

Under the terms of the deal, Cellution Biologics paid $8 million at closing, subject to agreed adjustments, with up to an additional $3 million in transition and commercial milestone payments over the following 18 months.

SimpliDerm is a hydrated human acellular dermal matrix designed for soft tissue repair and reconstruction, available in a range of configurations and sizes. The product has an existing commercial presence in the U.S. reconstructive surgery market, including established

Cellution Biologics buys SimpliDerm from Elutia for up to $11M

Tue, 18 Aug 2026 11:19:53 -0400

Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

Tue, 18 Aug 2026 11:19:00 -0400

ROSWELL, Ga., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cellution Biologics Inc. (“Cellution Biologics” or the “Company”), a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, today announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc. (Nasdaq: ELUT).

The acquisition marks Cellution Biologics’ entry into the U.S. reconstructive surgery market, adding a new surgical category to its existing portfolio across wound care, ocular repair and other surgical applications. SimpliDerm is an established human acellular dermal matrix with a proven commercial presence in

Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

Tue, 18 Aug 2026 11:19:00 -0400

Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

Tue, 18 Aug 2026 11:19:00 -0400

Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

Tue, 18 Aug 2026 11:19:00 -0400

Elutia sells SimpliDerm unit for up to $11M to fund NXT-41x

Tue, 18 Aug 2026 08:00:37 -0400

Elutia Inc. (Nasdaq: ELUT) has completed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics Inc. for total consideration of up to $11 million, according to a company statement.

The deal includes $8 million paid at closing, subject to adjustments for inventory levels and transaction expenses, plus up to $3 million in contingent milestone payments over the next 18 months.

Elutia said the proceeds represent non-dilutive capital that, combined with previously announced funding sources, the company believes is sufficient to support operations through the first full year of commercial launch of its NXT-41x product in 2028.

NXT-41x is an

Elutia sells SimpliDerm unit for up to $11M to fund NXT-41x

Tue, 18 Aug 2026 08:00:37 -0400

The deal includes $8 million paid at closing, subject to adjustments for inventory levels and transaction expenses, plus up to $3 million in contingent milestone payments over the next 18 months.

NXT-41x is an

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Tue, 18 Aug 2026 08:00:00 -0400

Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months
Divestiture further concentrates Elutia’s attention and resources on the development and commercialization of NXT-41x
NXT-41x is an antibiotic-eluting biomatrix designed to address post-operative infection in the $1.5 billion U.S. plastic and reconstructive surgery market
NXT-41x clearance expected in the first half of 2027

GAITHERSBURG, Md., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Tue, 18 Aug 2026 08:00:00 -0400

Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months
Divestiture further concentrates Elutia’s attention and resources on the development and commercialization of NXT-41x
NXT-41x is an antibiotic-eluting biomatrix designed to address post-operative infection in the $1.5 billion U.S. plastic and reconstructive surgery market
NXT-41x clearance expected in the first half of 2027

GAITHERSBURG, Md., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Tue, 18 Aug 2026 08:00:00 -0400

Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months
Divestiture further concentrates Elutia’s attention and resources on the development and commercialization of NXT-41x
NXT-41x is an antibiotic-eluting biomatrix designed to address post-operative infection in the $1.5 billion U.S. plastic and reconstructive surgery market
NXT-41x clearance expected in the first half of 2027

GAITHERSBURG, Md., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Tue, 18 Aug 2026 08:00:00 -0400

Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months
Divestiture further concentrates Elutia’s attention and resources on the development and commercialization of NXT-41x
NXT-41x is an antibiotic-eluting biomatrix designed to address post-operative infection in the $1.5 billion U.S. plastic and reconstructive surgery market
NXT-41x clearance expected in the first half of 2027

GAITHERSBURG, Md., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced

Form S-8 ELUTIA INC.

Fri, 14 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26932555.html

Form S-8 ELUTIA INC.

Fri, 14 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26932555.html

Form 10-Q ELUTIA INC. For: Jun 30

Fri, 14 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260814/26932057.html

Form 10-Q ELUTIA INC. For: Jun 30

Fri, 14 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260814/26932057.html

Form SCHEDULE 13G/A ELUTIA INC. Filed by: SILVERARC CAPITAL MANAGEMENT, LLC

Fri, 14 Aug 2026 12:47:00 -0400

si-local-file:///var/storage/secattach/20260814/26928028.html

Form SCHEDULE 13G/A ELUTIA INC. Filed by: SILVERARC CAPITAL MANAGEMENT, LLC

Fri, 14 Aug 2026 12:47:00 -0400

si-local-file:///var/storage/secattach/20260814/26928028.html

Elutia Inc. (ELUT) Misses Q2 EPS by 2c

Thu, 13 Aug 2026 16:20:35 -0400

Elutia Inc. (NASDAQ: ELUT) reported Q2 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $2.43 million versus the consensus estimate of $3 million.

For earnings history and earnings-related data on Elutia Inc. (ELUT) click here.

Form 8-K ELUTIA INC. For: Aug 13

Thu, 13 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260813/26921360.html

Form 8-K ELUTIA INC. For: Aug 13

Thu, 13 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260813/26921360.html